Lundbeck Inc. Presents New Data on Selincro From Three Phase III Studies That Consistently Show a Significant Reduction in Alcohol Consumption in Alcohol Dependent Patients With High Risk Drinking Level
• Patients treated with Selincro® (nalmefene) showed a reduction in total alcohol consumption after 6 months of 57% in study 1 (ESENSE 1)1 and 62% in study 2 (ESENSE 2)2 and after 12 months of 67% in study 3 (SENSE)3 among high risk drinking alcohol dependent patients.
• Selincro is the first and only medicine approved for the reduction of alcohol consumption in patients with alcohol dependence.4
•There is a significant unmet need as alcohol dependence is both underdiagnosed and undertreated. In Europe more than 90% of the patients with alcohol dependence are currently untreated.5,6
H. Lundbeck A/S (Lundbeck) announced today the results of the revised analysis of the Phase III programme that formed the basis for the approval of Selincro® (nalmefene) in the EU on February 25, 2013. Alcohol dependent patients with high risk drinking level (>60g/day for men, >40g/day for women) treated with Selincro showed a significant reduction in total alcohol consumption after 6 months of 57% in study 1 (ESENSE 1)1 and 62% in study 2 (ESENSE 2),2 and after 12 months of 67% in study 3 (SENSE).3 The analyses from these randomized, double-blind, placebo-controlled Phase III studies were presented at the 21st European Congress of Psychiatry (EPA) in Nice, France.